52334-53-9

Basic information

• Product Name: 4-AMINO-3-HYDROXY PYRIDINE
• Synonyms: 3-HYDROXY-4-AMINOPYRIDINE;4-AMINO-PYRIDIN-3-OL;4-AMINO-3-HYDROXY PYRIDINE;4-AMINO-3-HYDROXYPYRIDINE HYDROCHLORIDE;4-Amino-3-pyridinol hydrochloride;4-Amino-pyridin-3-ol HBr;4-Aminopyridin-3-ol hydrochloride;3-Pyridinol, 4-amino-
• CAS NO: 52334-53-9
• Molecular Formula: C₅H₆N₂O
• Molecular Weight: 110.11
• EINECS: -0
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;pharmacetical;Pyridine series;Amines;Pyridines;Pyridine;Building Blocks;Aromatics;Heterocycles;Metabolites & Impurities
• Mol File: 52334-53-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 222-223°C
• Boiling Point: 447.412 °C at 760 mmHg
• Flash Point: 224.387 °C
• Appearance: /
• Density: 1.32 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.651
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 10.78±0.12(Predicted)
• CAS DataBase Reference: 4-AMINO-3-HYDROXY PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-3-HYDROXY PYRIDINE(52334-53-9)
• EPA Substance Registry System: 4-AMINO-3-HYDROXY PYRIDINE(52334-53-9)

Safety Data

• Hazard Codes: Xi,T,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT, TOXIC
• Hazardous Substances Data: 52334-53-9(Hazardous Substances Data)

Usage

Uses

4-Amino-3-hydroxypyridine is a hydroxylated impurity as well as a metabolite of the potassium channel blocker Fampridine (D113500).

InChI:InChI=1/C5H6N2O/c6-4-1-2-7-3-5(4)8/h1-3,8H,(H2,6,7)

Upstream product

• 52334-90-4 4-amino-3-methoxy pyridine 
• 51581-40-9 3-pyridyl diethylcarbamate 
• 504-24-5 4-aminopyridine 
• 169205-93-0 3-Hydroxy-4-(pivalolylamino)pyridine 
• 142222-73-9 4-amino-3-pyridyl N,N-diethylcarbamate 
• 100130-15-2 3-hydroxy-4-aminopyridine sulfate 
• 70298-89-4 4-N-pivaloylaminopyridine 

Downstream Products

• 169205-98-5 2-Mercaptooxazolo<5,4-c>pyridine 
• 142222-57-9 N-Cyclohexyl-N'-(3-hydroxy-pyridin-4-yl)-N-methyl-formamidine 
• 143164-02-7 N-Benzyl-N'-(3-hydroxy-pyridin-4-yl)-N-methyl-formamidine 
• 142222-62-6 Phenyl-carbamic acid 4-(dimethylamino-methyleneamino)-pyridin-3-yl ester 
• 142222-90-0 Dimethyl-carbamic acid 4-[(cyclohexyl-methyl-amino)-methyleneamino]-pyridin-3-yl ester 
• 142222-92-2 Dimethyl-carbamic acid 4-[(benzyl-methyl-amino)-methyleneamino]-pyridin-3-yl ester 
• 194022-44-1 1H-Pyrido[3,4-b][1,4]oxazine-2-(3H)one 
• 68523-29-5 1H-oxazolo[5,4-c]pyridin-2-one 
• 169205-96-3 2-(Methylthio)oxazolo<5,4-c>pyridine 
• 121991-46-6 N-(3-benzoyloxy-[4]pyridyl)-dibenzamide 

Relevant articles and documents

HETEROCYCLIC DERIVATIVES

The present invention relates to heterocyclic derivatives, and more particularly, to novel heterocyclic derivatives useful for the preparation of medicaments for treating diseases related to uric acid.

Preparation of pyrido-1,4-oxazinylalkyl-benzamides for treating diseases mediated by platelet activating factor.

-

Aminopyridine carbamic acid esters: Synthesis and potential as acetylcholinesterase inhibitors and acetylcholine releasers

4-Amino-3-pyridyl carbamates (2a-c) were synthesized as potential acetylcholinesterase inhibitors and acetylcholine releasers on the basis of the reported activity of the analogous N-(4-amino-3-pyridyl)-N',N'- dimethylurea (1). Although 4-amino-3-pyridyl N,N-dimethylcarbamate (2b) showed good cholinesterase inhibition [concentration that elicited a 50% reduction in the maximal enzyme response (IC50) was 13.4 μM], it had no effect on the stimulated release of [3H]acetylcholine from rat striatal slices. 4-[[(Dimethylamino)methylene]amino]-3-pyridyl N,N-dimethylcarbamate (7a), an intermediate in the synthesis of 2b, demonstrated surprisingly good cholinesterase inhibition (IC50 was 9.4 μM) but showed no activity as a releaser. A precursor to 7a, N-(3-hydroxy-4-pyridyl)-N',N'- dimethylformamidine (6a), showed some activity in release but was not an esterase inhibitor, whereas the precursor to 6a, 4-amino-3-pyridinol (5a), was a potent releaser. A new synthesis of 5a, based on an ortho-directed lithiation strategy, is also reported.